FSN Capital has acquired a majority stake in Adragos Pharma, a Germany-based B2B contract developer and manufacturer (CDMO) for pharmaceuticals.
FSN Capital has acquired a majority stake in Adragos Pharma, a Germany-based B2B contract developer and manufacturer (CDMO) for pharmaceuticals.